Tom 8, Nr 4 (2016)
Artykuły
Opublikowany online: 2017-08-26
Wyświetlenia strony
877
Wyświetlenia/pobrania artykułu
5302
Choroba nowotworowa u pacjenta z nieswoistą chorobą zapalną jelit — zasady postępowania
Gastroenterologia Kliniczna 2016;8(4):119-130.
Streszczenie
Częstość występowania zarówno nieswoistych chorób zapalnych jelit (NChZJ), jak i nowotworów rośnie. Wyniki licznych badań wskazują także, że NChZJ oraz niektóre leki stosowane w ich terapii mogą sprzyjać rozwojowi powikłań onkologicznych. W niniejszym opracowaniu przedstawiono aktualny stan wiedzy, dotyczący czynników ryzyka zachorowania na nowotwory złośliwe w NChZJ, związane z przewlekłym zapaleniem w przewodzie pokarmowym, jak i z potencjalnym wpływem onkogennym wybranych leków immunosupresyjnych i biologicznych. Omówiono także zasady postępowania terapeutycznego w przypadku chorego z NChZJ, który chorował w przeszłości lub choruje aktualnie na nowotwór złośliwy. Dodatkowo zaprezentowano dane na temat wpływu leczenia onkologicznego na przebieg NChZJ, z uwzględnieniem roli nowych cząsteczek stosowanych w ramach immunoterapii schorzeń nowotworowych.
Słowa kluczowe: leczenie immunosupresyjnenieswoiste choroby zapalne jelitnowotwór złośliwyprzeciwciała anty-TNF-atiopuryny
Referencje
- Axelrad JE, Lichtiger S, Yajnik V. Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment. World J Gastroenterol. 2016; 22(20): 4794–4801.
- Sartor RB, Wu GD. Roles for Intestinal Bacteria, Viruses, and Fungi in Pathogenesis of Inflammatory Bowel Diseases and Therapeutic Approaches. Gastroenterology. 2017; 152(2): 327–339.e4.
- Colombel JF, Narula N, Peyrin-Biroulet L. Management Strategies to Improve Outcomes of Patients With Inflammatory Bowel Diseases. Gastroenterology. 2017; 152(2): 351–361.e5.
- Jauregui-Amezaga A, Vermeire S, Prenen H. Use of biologics and chemotherapy in patients with inflammatory bowel diseases and cancer. Ann Gastroenterol. 2016; 29(2): 127–136.
- Kaplan GG, Ng SC. Understanding and Preventing the Global Increase of Inflammatory Bowel Disease. Gastroenterology. 2017; 152(2): 313–321.e2.
- Shrestha MP, Ruel J, Taleban S. Healthcare maintenance in elderly patients with inflammatory bowel disease. Ann Gastroenterol. 2017; 30(3): 273–286.
- Annese V, Beaugerie L, Egan L, et al. ECCO. European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies. J Crohns Colitis. 2015; 9(11): 945–965.
- Beaugerie L, Itzkowitz SH, Beaugerie L, et al. Cancers complicating inflammatory bowel disease. N Engl J Med. 2015; 372(15): 1441–1452.
- Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001; 48(4): 526–535.
- Jess T, Simonsen J, Jørgensen KT, et al. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology. 2012; 143(2): 375–81.e1; quiz e13.
- Lutgens MW, van Oijen MGH, van der Heijden GJ, et al. Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis. 2013; 19(4): 789–799.
- Beaugerie L, Svrcek M, Seksik P, et al. CESAME Study Group. Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology. 2013; 145(1): 166–175.e8.
- Herrinton LJ, Liu L, Levin TR, et al. Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010. Gastroenterology. 2012; 143(2): 382–389.
- Ekbom A, Helmick CG, Zack M, et al. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med. 1990; 323(18): 1228–1233.
- Derikx LA, Nissen LHC, Smits LJT, et al. Risk of Neoplasia After Colectomy in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2016; 14(6): 798–806.e20.
- Abdalla M, Landerholm K, Andersson P, et al. Risk of Rectal Cancer After Colectomy for Patients With Ulcerative Colitis: A National Cohort Study. Clin Gastroenterol Hepatol. 2017; 15(7): 1055–1060.e2.
- Jess T, Gamborg M, Matzen P, et al. Increased risk of intestinal cancer in Crohn's disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol. 2005; 100(12): 2724–2729.
- Elriz K, Carrat F, Carbonnel F, et al. CESAME study group. Incidence, presentation, and prognosis of small bowel adenocarcinoma in patients with small bowel Crohn's disease: a prospective observational study. Inflamm Bowel Dis. 2013; 19(9): 1823–1826.
- Slesser AAP, Bhangu A, Bower M, et al. A systematic review of anal squamous cell carcinoma in inflammatory bowel disease. Surg Oncol. 2013; 22(4): 230–237.
- Glynne-Jones R, Nilsson PJ, Aschele C, et al. European Society for Medical Oncology (ESMO), European Society of Surgical Oncology (ESSO), European Society of Radiotherapy and Oncology (ESTRO). Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol. 2014; 40(10): 1165–1176.
- Erichsen R, Jepsen P, Vilstrup H, et al. Incidence and prognosis of cholangiocarcinoma in Danish patients with and without inflammatory bowel disease: a national cohort study, 1978-2003. Eur J Epidemiol. 2009; 24(9): 513–520.
- Singh S, Talwalkar JA. Primary sclerosing cholangitis: diagnosis, prognosis, and management. Clin Gastroenterol Hepatol. 2013; 11(8): 898–907.
- Tischendorf JJW, Meier PN, Strassburg CP, et al. Characterization and clinical course of hepatobiliary carcinoma in patients with primary sclerosing cholangitis. Scand J Gastroenterol. 2006; 41(10): 1227–1234.
- Razumilava N, Gores GJ, Lindor KD. Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology. 2011; 54(5): 1842–1852.
- Lindor KD, Kowdley KV, Harrison ME, et al. American College of Gastroenterology. ACG Clinical Guideline: Primary Sclerosing Cholangitis. Am J Gastroenterol. 2015; 110(5): 646–59; quiz 660.
- Said K, Glaumann H, Björnstedt M, et al. Gallbladder disease in patients with primary sclerosing cholangitis. J Hepatol. 2008; 48(4): 598–605.
- Mantzaris GJ. Thiopurines and Methotrexate Use in IBD Patients in a Biologic Era. Curr Treat Options Gastroenterol. 2017; 15(1): 84–104.
- Karran P, Attard N. Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer. Nat Rev Cancer. 2008; 8(1): 24–36.
- Pasternak B, Svanström H, Schmiegelow K, et al. Use of azathioprine and the risk of cancer in inflammatory bowel disease. Am J Epidemiol. 2013; 177(11): 1296–1305.
- Beaugerie L, Brousse N, Bouvier AM, et al. CESAME Study Group. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009; 374(9701): 1617–1625.
- Oh JK, Weiderpass E. Infection and cancer: global distribution and burden of diseases. Ann Glob Health. 2014; 80(5): 384–392.
- Kotlyar DS, Lewis JD, Beaugerie L, et al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol. 2015; 13(5): 847–58.e4; quiz e48.
- Sokol H, Beaugerie L, Maynadié M, et al. CESAME Study Group. Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2012; 18(11): 2063–2071.
- Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al. Cesame Study Group. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology. 2011; 141(5): 1621–16228.e1.
- Allegretti JR, Barnes EL, Cameron A. Are patients with inflammatory bowel disease on chronic immunosuppressive therapy at increased risk of cervical high-grade dysplasia/cancer? A meta-analysis. Inflamm Bowel Dis. 2015; 21(5): 1089–1097.
- Gutierrez-Dalmau A, Campistol JM. Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Drugs. 2007; 67(8): 1167–1198.
- Nyboe Andersen N, Pasternak B, Basit S, et al. Association between tumor necrosis factor-α antagonists and risk of cancer in patients with inflammatory bowel disease. JAMA. 2014; 311(23): 2406–2413.
- Singh S, Nagpal SJ, Murad MH, et al. Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2014; 12(2): 210–218.
- Bye WA, Jairath V, Travis SPL. Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2017; 46(1): 3–15.
- Beaugerie L, Carrat F, Colombel JF. Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. Gut . 2014; 63: 1416–1423.
- Axelrad J, Bernheim O, Colombel JF, et al. New York Crohn's and Colitis Organization. Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor Agents. Clin Gastroenterol Hepatol. 2016; 14(1): 58–64.
- Shelton E, Laharie D, Scott FI, et al. Cancer Recurrence Following Immune-Suppressive Therapies in Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis. Gastroenterology. 2016; 151(1): 97–109.e4.
- Beaugerie L, Peyrin-Biroulet L. No Excess Cancer Recurrence After Immunosuppressive Drugs in a Meta-analysis of Cohorts of Patients With Immune-mediated Diseases: A Mirage Related to Propensity Bias? Gastroenterology. 2017; 152(1): 304–306.
- Cosnes J. What Should Be Done in Inflammatory Bowel Disease Patients with Prior Malignancy? Dig Dis. 2017; 35(1-2): 50–55.
- Le PN, Greer JB, Oikonomou I, et al. IBD LIVE Case Series-Case 2: Previous Cancer in a Patient with Crohn's Disease: Is It Appropriate to Use Biologics and Immunosuppressants for IBD Treatment? Inflamm Bowel Dis. 2015; 21(6): 1401–1406.
- Tao Z, Li S, Ichim TE, et al. Cellular immunotherapy of cancer: an overview and future directions. Immunotherapy. 2017; 9(7): 589–606.
- Martin-Liberal J, Ochoa de Olza M, Hierro C, et al. The expanding role of immunotherapy. Cancer Treat Rev. 2017; 54: 74–86.
- Haanen JB, Thienen Hv, Blank CU. Toxicity patterns with immunomodulating antibodies and their combinations. Semin Oncol. 2015; 42(3): 423–428.
- Prieux-Klotz C, Dior M, Damotte D, et al. Immune Checkpoint Inhibitor-Induced Colitis: Diagnosis and Management. Target Oncol. 2017; 12(3): 301–308.
- Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review. JAMA Oncol. 2016; 2(10): 1346–1353.
- Bergqvist V, Hertervig E, Gedeon P, et al. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. Cancer Immunol Immunother. 2017; 66(5): 581–592.
- Chang BW, Kumar AMS, Koyfman SA, et al. Radiation therapy in patients with inflammatory bowel disease and colorectal cancer: risks and benefits. Int J Colorectal Dis. 2015; 30(3): 403–408.
- Bonovas S, Fiorino G, Lytras T, et al. Systematic review with meta-analysis: use of 5-aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017; 45(9): 1179–1192.
